Garth Cumberlidge

SemaThera, Inc. engages in research and development in biotechnology. It develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). The company is headquartered in Montreal, Canada.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Sigma Chemicals Co. is an American company that manufactures chemicals.

MP Bio medicals Canada Ulc provides genomics and gene delivery research tools and services. The firm’s products include PCR, transfection, protemics, lab tools and instruments, and enzyme products. It has operations in Canada, France, Switzerland and the United States. The company was founded in 1991 and is headquartered in Montréal, Canada.

Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.